Trastuzumab biosimilar - Glenmark PharmaceuticalsAlternative Names: GBR-200
Latest Information Update: 17 Mar 2017
At a glance
- Originator Glenmark Pharmaceuticals Ltd
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action ERBB 2 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Breast cancer
Most Recent Events
- 08 Mar 2017 Glenmark Pharmaceuticals plans a phase III trial for Breast cancer (Combination therapy, Metastatic disease) in India (CTRI2017-02-007892)